Topic: Primary Care Research Network for England, Cardiovascular
Conditions
Interventions
130 participants identified from the screening cohort will take part in the clinical trial. These people will have the highest central aortic systolic blood pressure (CASP) values from the screening
Sponsors
University College London (UK)
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Men aged 18-54 years (changed from "18 - 40 years" on 14/10/2016) 2. A diagnosis of stage 1 hypertension using conventional brachial BP measurements confirming a seated blood pressure of 140-159/90-99 3. No current treatment for hypertension (if previously treated with antihypertensives, patients will have received no treatment for >3 months) 4. Willing and capable of giving informed consent
Exclusion criteria
Exclusion criteria: 1. Women. 2. Men who have stage 2 hypertension, i.e. brachial blood pressure >=160/100 3. Men with secondary hypertension, e.g. renal artery stenosis, Conn?s adenoma, pheochromocytoma, aortic coarctation 4. Men who have stage 1 hypertension and on routine clinical testing have clinical evidence of overt target organ damage (e.g. ECG Left Ventricular hypertrophy LVH, renal impairment, proteinuria) 5. Cardiovascular disease (e.g. stroke, Transient Ischaemic Attack TIA, cardiac or peripheral vascular disease) 6. Diabetes mellitus i.e. risk factors that would indicate that the stage 1 hypertension should be treated according to current guidance (ref NICE guideline) 7. Men who are unable or unwilling to give written informed consent to participate in the study 8. Men in whom it is not possible to measure conventional brachial blood pressure 9. Men with atrial fibrillation or any other significant pulse rhythm irregularity in whom blood pressure measurement is difficult and unreliable 10. Regular consumption of an average of more than 28 units of alcohol per week, or use of recreational drugs 11. Men with chronic inflammatory diseases requiring concomitant medications with steroids and/or non steroidal antiinflammatory drugs 12. Men with concurrent nonspecific malignancy 13. Men unwilling to undergo MRI studies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular mass index; Timepoint(s): Baseline and study end (1 year treatment) | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed